HAVCR1 and diabetic kidney disease: Although novel biomarkers such as KIM-1 and TNFR2 are not yet recommended as standalone surrogate endpoints for DKD, they hold potential when used in combination with established markers, such as eGFR slope and urinary albumin change rate, to improve the prediction of ESRD risk.